Acquisition of extended-spectrum cephalosporin- and colistin-resistant Salmonella enterica subsp. enterica serotype Newport by pilgrims during Hajj

International Journal of Antimicrobial Agents
Abiola Olumuyiwa OlaitanJean-Marc Rolain

Abstract

Gatherings like the Hajj involving many people who travel from different parts of the world represent a risk for the acquisition and dissemination of infectious diseases. In this study, acquisition of multidrug-resistant (MDR) Salmonella spp. in 2013 Hajj pilgrims from Marseille, France, was investigated. In total, 267 rectal swabs were collected from 129 participants before their departure and after their return from the pilgrimage as well as during the pilgrimage from patients with diarrhoea. Samples were screened for the presence of Salmonella using quantitative real-time PCR and culture. Whole-genome sequencing was performed to characterise one of the isolates, and the mechanism leading to colistin resistance was investigated. Six post-Hajj samples and one sample collected during a diarrhoea episode in Hajj were positive for Salmonella by real-time PCR, with five Salmonella enterica belonging to several serotypes recovered by culture, whereas no pre-Hajj sample was positive. Two of the isolates belonged to the epidemic Newport serotype, were resistant to cephalosporins, gentamicin and colistin, and harboured the bla(CTX-M-2) gene and a 12-nucleotide deletion in the pmrB gene leading to colistin resistance. This study shows ...Continue Reading

References

Mar 5, 2003·International Journal of Antimicrobial Agents·Ziad A MemishQanta A Ahmed
Mar 28, 2006·Lancet·Qanta A AhmedZiad A Memish
Jun 1, 2007·Nucleic Acids Research·Ibtissem GrissaChristine Pourcel
Jul 4, 2007·Expert Reviews in Molecular Medicine·Abigail N Layton, Edouard E Galyov
Apr 1, 2009·Antimicrobial Agents and Chemotherapy·Song SunDan I Andersson
Jun 16, 2011·Nucleic Acids Research·You ZhouDavid S Wishart
Dec 24, 2011·The Lancet Infectious Diseases·Ibrahim AbubakarAli S Khan
Jun 28, 2012·PLoS Pathogens·Mark AchtmanUNKNOWN S. Enterica MLST Study Group
Feb 26, 2013·BMC Bioinformatics·Jan P Meier-KolthoffMarkus Göker
Jul 3, 2013·The Journal of Antimicrobial Chemotherapy·Jennie FischerBeatriz Guerra
Jul 11, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir BenkouitenPhilippe Gautret
Aug 24, 2013·The Lancet Infectious Diseases·L Silvia Munoz-PriceJohn P Quinn
Oct 1, 2013·International Journal of Antimicrobial Agents·Isabelle KempfEric Jouy
Oct 23, 2013·Antimicrobial Agents and Chemotherapy·Sushim Kumar GuptaJean-Marc Rolain
Nov 20, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir BenkouitenPhilippe Brouqui
Mar 25, 2014·Emerging Infectious Diseases·Philippe GautretPhilippe Parola
May 7, 2014·Travel Medicine and Infectious Disease·Philippe GautretDidier Raoult
May 27, 2014·Lancet·Ziad A MemishJaffar A Al-Tawfiq

❮ Previous
Next ❯

Citations

Dec 30, 2015·International Journal of Antimicrobial Agents·Abiola Olumuyiwa OlaitanSerge Morand
Mar 12, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H ErdemA Inan
May 29, 2016·International Journal of Antimicrobial Agents·Mohamed RhoumaAnn Letellier
Jun 5, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Moataz Abd El GhanyGrant A Hill-Cawthorne
Jul 16, 2016·PloS One·Christian Vinueza-BurgosLieven De Zutter
Aug 16, 2016·International Journal of Antimicrobial Agents·Sophie BaronAbiola Olumuyiwa Olaitan
May 27, 2017·The Journal of Antimicrobial Chemotherapy·Thongpan LeangapichartPhilippe Gautret
Jun 28, 2017·Travel Medicine and Infectious Disease·Thongpan LeangapichartPhilippe Gautret
Aug 17, 2018·PLoS Neglected Tropical Diseases·Mashal M AlmutairiPeter J Hotez
Jul 15, 2016·Clinical and Vaccine Immunology : CVI·Fabien J FucheSharon M Tennant
Mar 30, 2017·World Journal of Clinical Cases·Mohammad Irfan AzeemRobert Booy
Jul 1, 2018·Current Infectious Disease Reports·Kevin L Schwartz, Shaun K Morris
Sep 21, 2017·Emerging Infectious Diseases·Moataz Abd El GhanyZiad A Memish
Aug 30, 2018·Current Infectious Disease Reports·Van-Thuan Hoang, Philippe Gautret
Oct 1, 2020·Journal of Personalized Medicine·Vivian GarzónDaniel G Pinacho
Nov 21, 2019·Indian Journal of Medical Microbiology·Agila Kumari PragasamBalaji Veeraraghavan
Dec 16, 2020·Viruses·Laith N Al-EitanAnthony R Fooks
Apr 1, 2019·Indian Journal of Medical Microbiology·Agila Kumari PragasamBalaji Veeraraghavan
Sep 4, 2021·Frontiers in Medicine·Firdoos Ahmad GogryQazi Mohd Rizwanul Haq

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CRISPRi Screens for Antibiotics

The CRISPR-Cas system is a gene editing technique that can be used for high-throughput genome-wide screens to identify modes of actions of novel antibiotics. Here is the latest research.